University of Florida opens phase 2 of GLP-1 plus levonorgestrel IUD in endometrial neoplasia
The pilot trial, NCT07107334, enrolls obese patients with endometrioid intraepithelial neoplasia who are poor surgical candidates or want to preserve fertility.
PR
By Priya Raman · Science Reporter
Oct 21 08:00 ETSource: ClinicalTrials.gov
The wire
- 01The recruiting phase 2 pilot, which began April 7, 2026, tests a GLP-1 receptor agonist given alongside a levonorgestrel intrauterine device.
- 02It targets patients seeking fertility-sparing management or unable to undergo hysterectomy, a group with few nonsurgical options.
- 03The sponsor describes the work as estimating early efficacy signals; the role of GLP-1 agonists in endometrial cancer prevention and treatment remains unmeasured.
From the source
Read at clinicaltrials.govA Study to Estimate Early Clinical Efficacy Signals of GLP-1 Agonist Administration in Conjunction With Levonorgestrel Intrauterine Device in Obese Patients With Endometrioid Intraepithelial Neoplasia
NCT07107334 · PHASE2 · RECRUITING · Sponsor: University of Florida · Conditions: Endometrioid Endometrial Adenocarcinoma.
Source URL https://clinicaltrials.gov/study/NCT07107334
